NasdaqGM:CRBP

Stock Analysis Report

Executive Summary

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.

Share Price & News

How has Corbus Pharmaceuticals Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.3%

CRBP

3.1%

US Biotechs

1.8%

US Market


1 Year Return

-31.2%

CRBP

-7.9%

US Biotechs

7.3%

US Market

Return vs Industry: CRBP underperformed the US Biotechs industry which returned -7.9% over the past year.

Return vs Market: CRBP underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

CRBPIndustryMarket
7 Day7.3%3.1%1.8%
30 Day-8.9%-2.4%-0.7%
90 Day-17.5%-0.8%0.06%
1 Year-31.2%-31.2%-7.1%-7.9%9.7%7.3%
3 Year-44.2%-44.2%14.2%10.3%46.3%36.9%
5 Yearn/a0.07%-4.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Corbus Pharmaceuticals Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Corbus Pharmaceuticals Holdings undervalued compared to its fair value and its price relative to the market?

6.81x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: CRBP ($4.99) is trading above our estimate of fair value ($1.29)

Significantly Undervalued: CRBP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CRBP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CRBP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate CRBP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CRBP is overvalued based on its PB Ratio (6.8x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Corbus Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

42.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRBP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRBP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRBP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRBP's revenue (70.7% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CRBP's revenue (70.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if CRBP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Corbus Pharmaceuticals Holdings performed over the past 5 years?

-52.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CRBP is unprofitable, and losses have increased over the past 5 years at a rate of -52.4% per year.

Accelerating Growth: Unable to compare CRBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: CRBP has a negative Return on Equity (-118.19%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CRBP is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CRBP is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Corbus Pharmaceuticals Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: CRBP's short term assets ($75.4M) exceeds its short term liabilities ($29.4M)

Long Term Liabilities: CRBP's short term assets (75.4M) exceeds its long term liabilities (7.3M)


Debt to Equity History and Analysis

Debt Level: CRBP's debt to equity ratio (0.2%) is considered satisfactory

Reducing Debt: CRBP's debt to equity ratio has reduced from 8.5% to 0.2% over the past 5 years.


Balance Sheet

Inventory Level: CRBP has a low level of unsold assets or inventory.

Debt Coverage by Assets: CRBP's debt is covered by short term assets (assets are 758.970960x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRBP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CRBP has less than a year of cash runway if free cash flow continues to reduce at historical rates of -29% each year


Next Steps

Dividend

What is Corbus Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CRBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CRBP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CRBP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRBP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRBP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Corbus Pharmaceuticals Holdings's salary, the management and board of directors tenure and is there insider trading?

5.2yrs

Average management tenure


CEO

Yuval Cohen (44yo)

5.5yrs

Tenure

US$3,572,460

Compensation

Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc  ...


CEO Compensation Analysis

Compensation vs. Market: Yuval's total compensation ($USD3.57M) is about average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Yuval's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

5.2yrs

Average Tenure

61yo

Average Age

Experienced Management: CRBP's management team is seasoned and experienced (5.2 years average tenure).


Board Age and Tenure

4.4yrs

Average Tenure

47yo

Average Age

Experienced Board: CRBP's board of directors are considered experienced (4.4 years average tenure).


Insider Trading

Insider Buying: CRBP insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$8,21316 Aug 19
Craig Millian
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares1,500
Max PriceUS$5.48
BuyUS$9,99813 Aug 19
Barbara White
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares1,639
Max PriceUS$6.10
BuyUS$9,00013 Aug 19
Craig Millian
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares1,500
Max PriceUS$6.00
BuyUS$7,11612 Aug 19
Yuval Cohen
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares1,175
Max PriceUS$6.06
BuyUS$87,89412 Aug 19
Robert Discordia
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares15,000
Max PriceUS$5.86
BuyUS$10,00120 May 19
Barbara White
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares1,389
Max PriceUS$7.20
BuyUS$7,22715 May 19
Craig Millian
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares1,000
Max PriceUS$7.23
BuyUS$71214 May 19
Sean Moran
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares100
Max PriceUS$7.12
BuyUS$6,95514 May 19
Yuval Cohen
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares995
Max PriceUS$6.99
BuyUS$13,95818 Mar 19
David Hochman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,000
Max PriceUS$6.98
BuyUS$6,97815 Mar 19
John Jenkins
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,000
Max PriceUS$6.98
BuyUS$34,25915 Mar 19
Craig Millian
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares5,000
Max PriceUS$6.85
BuyUS$29,99414 Mar 19
Barbara White
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares4,638
Max PriceUS$6.47
BuyUS$10,00514 Mar 19
Sean Moran
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,500
Max PriceUS$6.67
BuyUS$9,93014 Mar 19
Yuval Cohen
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares1,530
Max PriceUS$6.49

Ownership Breakdown


Management Team

  • Sean Moran (61yo)

    Chief Financial Officer

    • Tenure: 5.5yrs
    • Compensation: US$1.24m
  • Mark Tepper (62yo)

    Co-Founder & Consultant

    • Tenure: 0.5yrs
    • Compensation: US$1.66m
  • Yuval Cohen (44yo)

    CEO & Director

    • Tenure: 5.5yrs
    • Compensation: US$3.57m
  • Barbara White (69yo)

    Chief Medical Officer

    • Tenure: 5.2yrs
    • Compensation: US$1.69m
  • Craig Millian (51yo)

    Chief Commercial Officer

    • Tenure: 0.7yrs
  • Scott Constantine

    Senior Director & Head of Clinical Operations

    • Tenure: 0yrs
  • Robert Discordia

    Chief Operating Officer

    • Tenure: 0yrs
  • Ted Jenkins

    Senior Director of Investor Relations & Communications

    • Tenure: 0yrs
  • Sergei Atamas

    Executive Director of Research

    • Tenure: 0yrs

Board Members

  • Chip Catlin (71yo)

    Director

    • Tenure: 5.2yrs
    • Compensation: US$213.62k
  • David Hochman (44yo)

    Director

    • Tenure: 5.8yrs
    • Compensation: US$205.20k
  • Alan Holmer (69yo)

    Chairman

    • Tenure: 5.5yrs
    • Compensation: US$238.71k
  • Yuval Cohen (44yo)

    CEO & Director

    • Tenure: 5.5yrs
    • Compensation: US$3.57m
  • Charles Serhan

    Member of Scientific Advisory Board

    • Tenure: 4.4yrs
  • George Kunos

    Member of Scientific Advisory Board

    • Tenure: 1.1yrs
  • Paris Panayiotopoulos (45yo)

    Director

    • Tenure: 2yrs
    • Compensation: US$215.96k
  • Michael Knowles

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • John Jenkins (61yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$325.35k
  • Rachelle Jacques (47yo)

    Director

    • Tenure: 0.5yrs

Company Information

Corbus Pharmaceuticals Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Corbus Pharmaceuticals Holdings, Inc.
  • Ticker: CRBP
  • Exchange: NasdaqGM
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$322.611m
  • Shares outstanding: 64.65m
  • Website: https://www.corbuspharma.com

Number of Employees


Location

  • Corbus Pharmaceuticals Holdings, Inc.
  • 500 River Ridge Drive
  • Norwood
  • Massachusetts
  • 2062
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRBPNasdaqGM (Nasdaq Global Market)YesNew Common SharesUSUSDOct 2014
337DB (Deutsche Boerse AG)YesNew Common SharesDEEUROct 2014
0SZILSE (London Stock Exchange)YesNew Common SharesGBUSDOct 2014

Biography

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 00:37
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.